After announcing a deal with Recipharm for development of two inhaled drugs (TRB-1 and TRB-2) earlier this year, Transpire Bio says that it has signed an agreement with the CDMO for development of an additional two inhaled products. Under the new agreement, Recipharm will provide development services for Transpire’s TRB-3 and TRB-4 inhaled therapeutics for the treatment of asthma and COPD.
According to Transpire Bio’s web site, the company is “dedicated to developing and bringing to the market lower-cost, high-quality generic alternatives across all inhaler types.” The web page about Transpire’s pipeline does not identify specific candidates but indicates that the pipeline includes one generic MDI, one generic DPI, and one generic SMI for asthma plus one generic MDI, one generic DPI, and one generic SMI for COPD.
Transpire CEO Xian-Ming Zeng commented, “We are continuing our relentless pursuit of improving access to important, life-saving inhaled therapies, while methodically building capabilities for new inhaled therapies which will help address areas of significant unmet medical need. With TRB-3 and TRB-4, we are demonstrating our ability to rapidly progress our pipeline in an effort to meet patient needs as quickly as possible. We are very excited to again be working with Recipharm to advance these important medicines.”
Recipharm Head of the Advanced Delivery Systems Business Unit Jean-Francois Hilaire said, “TRB-3 and TRB-4 are exciting developments for the treatment of two increasingly common chronic respiratory conditions. Recipharm is delighted to collaborate with Transpire Bio again and we will continue to share our extensive experience and expertise in developing and commercializing inhalation products to help bring these new inhaled medicines to market.”
Read the Recipharm and Transpire Bio press release.
